Raymond E. Galinsky
Purdue University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Raymond E. Galinsky.
Pharmacogenetics | 2000
Lan Yan; Raymond E. Galinsky; Jonathan A. Bernstein; Stephen B. Liggett; Richard M. Weinshilboum
Histamine is involved in the pathophysiology of asthma, and histamine N-methyltransferase (HNMT) plays the dominant role in histamine metabolism in human bronchial epithelium. Levels of HNMT activity in human tissues are controlled, in part, by inheritance. A common C314T polymorphism within the HNMT gene results in a Thr105Ile change in encoded amino acid, and the T314 allele is associated with decreased levels of both HNMT enzymatic activity and immunoreactive protein. Therefore, presence of the T314 allele would be expected to result in reduced histamine metabolism and increased bronchoconstriction. We characterized this common, functionally significant polymorphism in DNA samples from 237 randomly selected Caucasian control subjects and 192 samples from Caucasian asthmatic patients. Allele frequencies for the T314 HNMT allele were 0.08 in the control samples and 0.14 in samples from Caucasian asthmatic patients (odds ratio = 1.9, P < 0.01), indicating a significant increase in the frequency of subjects with low HNMT activity among asthmatics. The association between a common, functionally significant genetic polymorphism for HNMT and asthma suggests that individual variation in histamine metabolism might contribute to the pathophysiology and/or response to therapy of this disease.
Endocrinology | 2010
Sung Won Park; Sooyoung Shin; Chi Hwa Kim; Ah-Ra Ko; Min Jung Kwak; Mi Hyun Nam; So Young Park; Su Jin Kim; Young Bae Sohn; Raymond E. Galinsky; Hojoong Kim; Yoon Yeo; Dong-Kyu Jin
The objective of this study was to characterize the effect of inhalable growth hormone (GH) delivered by an insufflator to the lungs of hypophysectomized Sprague Dawley rats. In the first cohort, the safety and efficacy of the insufflated GH were evaluated. Three experimental groups (n = 7 per group) were treated with GH for 15 d: One group received sc injection of GH daily at 200 microg/kg (SC200). Two other groups received GH by insufflation daily: 200 microg/kg (INS 200) and 600 microg/kg (INS 600). In the second set of experiments, GH was administered in three routes [SC200, INS200, intravenous (IV200)] (n=10) for 5 d, and escape latency and N-methyl D-aspartate (NMDA) receptor expression were evaluated. In the first cohort, INS200 showed similar bioactivity as SC200 in growth promotion, tibial growth, as well as escape latency on the 12th day of treatment. Insufflated GH was well tolerated without significant inflammatory responses. In the second cohort, expression of the NMDA receptor 1 and 2B in hippocampus measured after 3 or 6 d of daily treatments were significantly higher in INS200 as compared to IV200, consistent with the improvement of the escape latency. In summary, the inhalable form of GH delivered by intratracheal insufflation was safe, and its bioactivity was comparable to sc injection both in promotion of growth and acquisition of learning ability. If applied properly to human, inhalable GH would be effective for growth promotion and possibly for several disorders caused by underexpression of NMDA receptors.
Clinical Pharmacology & Therapeutics | 1999
L. Yan; Raymond E. Galinsky; Stephen B. Liggett; Richard M. Weinshilboum
Clinical Pharmacology & Therapeutics (1999) 65, 146–146; doi:
Hepatology | 2001
Naga Chalasani; J. Christopher Gorski; Nilesh H. Patel; Stephen D. Hall; Raymond E. Galinsky
British Journal of Clinical Pharmacology | 2004
Bryan A. Ward; Alan Morocho; Abdullah Kandil; Raymond E. Galinsky; David A. Flockhart; Zeruesenay Desta
Veterinary Therapeutics | 2008
Lisa A. Abbo; Jeff C. Ko; Lara K. Maxwell; Raymond E. Galinsky; David E. Moody; Brenda M. Johnson; Wenfang B. Fang
Toxicological Sciences | 2004
Xinzhu Pu; Linda S. Lee; Raymond E. Galinsky; Gary P. Carlson
Toxicology | 2006
Xinzhu Pu; Linda S. Lee; Raymond E. Galinsky; Gary P. Carlson
Clinical Pharmacology & Therapeutics | 2001
J. C. Gorski; Naga Chalasani; Nilesh H. Patel; Raymond E. Galinsky; R. Craven; Stephen D. Hall
PMC | 2016
Zeruesenay Desta; Ingrid F. Metzger; Nancy Thong; Jessica Bo Li Lu; John T. Callaghan; Todd C. Skaar; David A. Flockhart; Raymond E. Galinsky